Physician profile
Matthew Callaway
NPI 1770578718
$2,902.09
in general payments reported to CMS, 2019-2025
28 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $476 · 2021: $314 · 2022: $322 · 2023: $484 · 2024: $438 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,030 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.93 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $509.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $454.75 | 2019-2025 | Veozah |
| Abbvie INC. | $205.30 | 2021-2025 | Ubrelvy |
| Boston Scientific Corporation | $187.11 | 2020-2023 | Watchman, Watchman Access System |
| Glaxosmithkline, LLC. | $156.29 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $151.79 | 2019-2023 | Verquvo, Belsomra |
| Pfizer INC. | $134.27 | 2020-2025 | |
| Amgen INC. | $125.40 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.67 | 2019-2022 | |
| Medtronic Minimed, INC. | $102.75 | 2019 | |
| Amarin Pharma, INC. | $85.71 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.36 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $75.63 | 2022 | |
| Novartis Pharmaceuticals Corporation | $73.38 | 2020-2025 | |
| Exact Sciences Corporation | $71.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $69.63 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $59.91 | 2019-2022 | |
| Genentech USA, INC. | $43.62 | 2019-2020 | |
| Celgene Corporation | $41.91 | 2019 | |
| Mylan Specialty L.P. | $30.10 | 2021 | |
| Esperion Therapeutics, INC. | $23.82 | 2021 | |
| Medtronic, INC. | $20.00 | 2025 | Minimed 780g |
| Kowa Pharmaceuticals America, INC. | $17.67 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.59 | 2023 | Evusheld |
| Teva Pharmaceuticals USA, INC. | $11.38 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.23 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $11.17 | 2021 | |
| Lilly USA, LLC | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Callaway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.